Vol. 45 (5): 873-876, September – October, 2019
doi: 10.1590/S1677-5538.IBJU.2019.05.02
EDITORIAL
Armando Stabile 1, Marco Moschini 2, Francesco Montorsi 1, Xavier Cathelineau 3, Rafael Sanchez-Salas 3
1 Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; 2 Klinik fur Urologie, Luzerner Kantonsspital, Lucerne, Switzerland; 3 Department of Urology, Institut Mutualiste Montsouris and Universite Paris Descartes, Paris, France
Current standard of care for localized prostate cancer (PCa) include active surveillance and radical therapy. Tissue-sparing approaches such as focal therapy (FT) has recently emerged to cover that middle ground between active surveillance and whole gland therapies in order to provide cancer control while reducing morbidities and side-effects. Evidence from a systematic review including thirty-seven studies reporting on 3230 patients receiving FT through different energy sources reported a rate of significant disease (csPCa) at follow-up biopsy ranging between 0% and 13% within a median follow-up ranging from 4 to 61 months. Leak-free continence and potency rate were 83.3-100% and 81.5-100%, respectively (1)
